EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio
Portfolio Pulse from Vandana Singh
Clearmind Medicine Inc (NASDAQ:CMND) has filed a provisional patent application for the treatment of Dyskinesia with the US Patent and Trademark Office. The patent application refers to the psychedelic molecule 3-Methylmethcathinone (3-MMC) as a potential treatment for Dyskinesia. The patent application also includes protection for its unique combination of 3-MMC and SciSparc's Palmitoylethanolamide for Dyskinesia as part of its ongoing collaboration with SciSparc Ltd (NASDAQ:SPRC).
August 01, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearmind's new patent application for Dyskinesia treatment could strengthen its IP portfolio and potentially open new revenue streams if the treatment proves successful.
The filing of a new patent application indicates Clearmind's active efforts in expanding its product portfolio. If the patent is granted and the treatment proves successful, it could potentially increase the company's revenues and positively impact its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
SciSparc's collaboration with Clearmind on the Dyskinesia treatment patent application could potentially enhance its reputation and partnership portfolio.
SciSparc's involvement in the patent application through its collaboration with Clearmind could potentially enhance its reputation in the industry and strengthen its partnership portfolio. This could have a positive impact on its stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70